Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing micronized human vascular endostatin

A technology of vascular endothelium and composition, which is applied in the field of preparation of human vascular endostatin pharmaceutical composition, can solve the problems of low solubility of protein and polypeptide drugs, achieve the effects of reducing the number of administrations, facilitating adjustment, and improving compliance

Active Publication Date: 2010-02-10
SHANDONG SIMCERE BIO PHARMA CO LTD +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Supercritical fluid technology is a newly developed technology that can use the properties of supercritical fluid to extract solvents and dry proteins. However, there are still many problems that need to be studied and solved in this technology: such as the solubility of proteins and peptide drugs in organic solvents Generally small, how to increase the solubility of the drug by changing the solvent composition, and the relationship between different operating conditions and the final micropowder with different properties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing micronized human vascular endostatin
  • Pharmaceutical composition containing micronized human vascular endostatin
  • Pharmaceutical composition containing micronized human vascular endostatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Precisely measure 50ml of recombinant human endostatin Endostar protein solution (9.1462mg / ml, PH=5.5), add 0.004% zinc acetate, until the zinc salt is completely dissolved, regulate the protein with sodium hydroxide solution (1mol / L) The pH of the solution is in the range of 8.8-9.3. At this point, a large amount of protein precipitated, and the solution was milky white. Add 50ml of PEG-8000 solution with a concentration of 50% (w / v), and stir magnetically for 5 minutes to make it evenly mixed. The above-prepared solution was divided into 30ml vials, the filling specification was 5ml / bottle, and freeze-dried. Dissolve the freeze-dried product with dichloromethane, dissolve PEG-8000 in dichloromethane, and after centrifugation, obtain micronized protein containing dichloromethane at the bottom of the centrifuge tube, dry it under reduced pressure at room temperature, and obtain dry micronized protein. 2 g of PLGA (Mw=50000, lactic acid:glycolic acid=50:50) was dissolve...

Embodiment 2

[0045] Accurately measure 50ml of recombinant human endostatin protein Endostar solution (9.1462mg / ml, PH=5.5), add 0.004% zinc acetate, until the zinc salt is completely dissolved, regulate the protein with sodium hydroxide solution (1mol / L) The pH of the solution is in the range of 8.8-9.3. At this point, a large amount of protein precipitated, and the solution was milky white. Add 50ml of PEG-8000 solution with a concentration of 50% (w / v), and stir magnetically for 5 minutes to make it evenly mixed. The above-prepared solution was divided into 30ml vials, the filling specification was 5ml / bottle, and freeze-dried. Dissolve the lyophilized product with dichloromethane, and dissolve PEG-8000 in dichloromethane. After centrifugation, micronized protein containing dichloromethane is obtained at the bottom of the centrifuge tube, and dried under reduced pressure at room temperature to obtain dry micronized protein. The composition powder was dissolved with 2 ml of dichlorometh...

Embodiment 3

[0049] Get the microsphere prepared by embodiment two to carry out the biological activity assay of Endostar

[0050] 1. HUVEC cells were cultured with ECM supplemented with FBS, ECGS, and P / O Solution at 37°C, 5% CO 2 Cultured in an incubator, and inoculated after the cells were in good condition and entered the logarithmic growth phase.

[0051] 2. Digest the cells with 0.25% trypsin, centrifuge at 1000rpm for 5min, discard the supernatant, resuspend with the medium, and count live cells with a hemocytometer under a microscope. Adjust the cell density to 5000 cells / ml, add 160 μl of cell suspension to each well, and store at 37°C in 5% CO 2 cultured in an incubator.

[0052] 3. Pre-dilute the endostar stock solution and the extract obtained during the determination of the content of Endostar microspheres with pH 7.4 phosphate buffer to 2.5mg / ml, and the final concentration in the well is 500, 250, 125, 62.5, 31.25, 15.625 , 0μg / ml, add 40μl drug volume to each well, set 3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Volume average particle sizeaaaaaaaaaa
Volume average particle sizeaaaaaaaaaa
Weight average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a pharmaceutical composition containing micronized solid human vascular endostatin serving as an active component and a preparation method for the composition. The pharmaceutical composition contains a medicinal carrier and the micronized solid human vascular endostatin, wherein the medicinal carrier can be a lacti-glycolic acid polymer. The pharmaceutical composition canalso contain 0.5 to 30 weight percent of protective agent.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing human vascular endostatin in micronized solid form, in particular to a preparation method of a human vascular endostatin pharmaceutical composition with good activity. Background technique [0002] Studies have found that during the growth and metastasis of solid tumors, angiogenesis is needed to provide nutrition. At this time, tumor cells will send some signals to promote the proliferation of blood vessels to tumor tissues. Some endogenous angiogenesis inhibitors such as Angiostatin and Endostatin can hinder The growth of blood vessels in tumor tissue stagnates tumor growth and metastasis (O'Relly, M.S., et al. Cell.79:315-328, 1994; O'Relly, M.S., et al Cell.88:277- 285, 1997), Professor Folkman of Harvard Medical School in the United States proposed the theory of "starving tumor therapy" by using endostatin (Endostatin) to inhibit tumor growth in the 1970s. However, due to the proble...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K47/34A61K47/36A61P35/00
Inventor 陈英杰李海瑞王青松许向阳
Owner SHANDONG SIMCERE BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com